New technology to enhance the immune system's ability to fight cancer
SIRPant Technology for anti-Cancer Immunity
['FUNDING_OTHER'] · SIRPANT IMMUNOTHERAPEUTICS, INC. · NIH-10919238
This study is looking at a new way to help your immune system fight cancer by using a special treatment that boosts certain immune cells to better attack tumors, which could lead to improved outcomes for patients with advanced cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SIRPANT IMMUNOTHERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (Hummelstown, UNITED STATES) |
| Trial ID | NIH-10919238 on ClinicalTrials.gov |
What this research studies
This research focuses on overcoming cancer's ability to evade the immune system by targeting a specific protein called CD47. The approach involves using a proprietary reagent known as 'Phago-Act' to enhance the function of certain immune cells, specifically macrophages, which can then effectively attack and eliminate cancer cells. By improving the immune response, this research aims to activate tumor-specific T cells that can target and destroy solid tumors, particularly in advanced stages. Patients may benefit from a more effective treatment option that could lead to better outcomes in cancer therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with late-stage solid tumors, including breast and colorectal cancers.
Not a fit: Patients with early-stage cancers or those whose tumors do not express CD47 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel immunotherapy that significantly improves the effectiveness of cancer treatments.
How similar studies have performed: Other research has shown promising results in enhancing immune responses against cancer using similar immunotherapy approaches, indicating potential for success.
Where this research is happening
Hummelstown, UNITED STATES
- SIRPANT IMMUNOTHERAPEUTICS, INC. — Hummelstown, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCCURLEY, NATHANAEL — SIRPANT IMMUNOTHERAPEUTICS, INC.
- Study coordinator: MCCURLEY, NATHANAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer